Merck & Co., Inc. (NYSE:MRK) Shares Sold by Pacific Wealth Strategies Group Inc.

Share on StockTwits

Pacific Wealth Strategies Group Inc. decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 40.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,625 shares of the company’s stock after selling 12,875 shares during the quarter. Pacific Wealth Strategies Group Inc.’s holdings in Merck & Co., Inc. were worth $1,694,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Atwater Malick LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth about $57,000. 1 North Wealth Services LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth about $58,000. American National Bank bought a new position in Merck & Co., Inc. in the 3rd quarter worth about $67,000. Lenox Wealth Management Inc. grew its position in Merck & Co., Inc. by 23.3% in the 3rd quarter. Lenox Wealth Management Inc. now owns 793 shares of the company’s stock worth $67,000 after purchasing an additional 150 shares during the last quarter. Finally, Balentine LLC grew its position in Merck & Co., Inc. by 58.4% in the 3rd quarter. Balentine LLC now owns 933 shares of the company’s stock worth $79,000 after purchasing an additional 344 shares during the last quarter. Hedge funds and other institutional investors own 74.50% of the company’s stock.

Merck & Co., Inc. stock opened at $91.54 on Thursday. The firm has a 50 day simple moving average of $89.80 and a 200-day simple moving average of $85.55. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.26 and a quick ratio of 0.98. The stock has a market capitalization of $228.96 billion, a PE ratio of 21.09, a price-to-earnings-growth ratio of 1.80 and a beta of 0.52. Merck & Co., Inc. has a 12-month low of $72.05 and a 12-month high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion during the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The business’s revenue was up 14.9% on a year-over-year basis. During the same period last year, the firm posted $1.19 earnings per share. On average, analysts forecast that Merck & Co., Inc. will post 5.15 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th were issued a $0.61 dividend. The ex-dividend date of this dividend was Friday, December 13th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 annualized dividend and a dividend yield of 2.67%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 56.22%.

Several research analysts have commented on the stock. Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Royal Bank of Canada assumed coverage on shares of Merck & Co., Inc. in a research report on Monday, January 6th. They issued a “sector perform” rating and a $99.00 target price for the company. Mizuho restated a “buy” rating and issued a $100.00 target price on shares of Merck & Co., Inc. in a research report on Monday, January 6th. Cantor Fitzgerald restated a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Finally, Bank of America assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $95.69.

In other news, EVP Julie L. Gerberding sold 102,073 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $89.34, for a total value of $9,119,201.82. Following the completion of the transaction, the executive vice president now directly owns 106,099 shares in the company, valued at $9,478,884.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: What is the Shanghai Stock Exchange Composite Index?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.